ADVERTISEMENT
StimLabs
06/12/2024
StimLabs announces IRB approval for CAMPSTIM, the largest RCT trial to demonstrate the efficacy of multiple placental-based tissue products for treatment of hard-to-heal DFUs. CAMPSTIM will evaluate at least four CAMPs (Enverse, Revita, Relese and Cogenex) and enroll 272 patients in the US.